Methods of transdermally delivering a therapeutic amount of an indole serotonin receptor agonist to an individual in need thereof, e.g., to provide a therapeutic level of an indole serotonin receptor agonist to an individual in need thereof, are provided. Also provided are transdermal formulations of indole serotonin receptor agonists that find use in practicing the subject methods.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 provides a cross-sectional view of a transdermal patch preparation according to the invention.
FIGS. 2 & 3 provide graphical representations of results reported in the Experimental section, below.
Claims
1. A method of delivering a therapeutic amount of an indole serotonin receptor agonist to an individual in need thereof, the method comprising contacting a topical surface of said individual with a transdermal formulation comprising said indole receptor serotonin agonist.
2. The method according to claim 1, wherein said transdermal formulation is a patch, a gel, a cream, a foam, a lotion, a spray, an ointment.
3. The method according to claim 2, wherein said transdermal formulation is a patch formulation comprising an adhesive polymer.
4. The method according to claim 3, wherein said method comprising adhering said patch formulation to a skin surface of the individual.
5. The method of claim 1, wherein said method is a method of treating a headache.
6. The method of claim 1, wherein said method is a method of preventing a headache.
7. The method of claim 1, wherein the method provides for a level of indole serotonin receptor agonist in the individual that is effective to inhibit migraine pain.
8. The method of claim 1, wherein the method provides a substantially constant level of an indole serotonin receptor agonist in the individual over an extended period of time.
9. A method of preventing a headache in an individual, the method comprising contacting a topical surface of said individual with a transdermal formulation comprising an indole receptor serotonin agonist.
10. The method according to claim 9, wherein said transdermal formulation is a patch, a gel, a cream, a foam, a lotion, a spray, or an ointment.
11. The method according to claim 9, wherein said transdermal formulation is a patch formulation comprising an adhesive polymer.
12. The method according to claim 11, wherein said contacting comprises adhering said patch formulation to a skin surface of the individual.
13. The method according to claim 9, wherein said headache is a migraine headache.
14. The method of claim 9, wherein the method provides a substantially constant level of an indole serotonin receptor agonist in the individual over an extended period of time.
15. A method of treating an individual for a headache, said method comprising: contacting a topical surface of said individual with a transdermal formulation comprising an indole receptor serotonin agonist.
16. The method according to claim 15, wherein said transdermal formulation is a patch, a gel, a cream, a foam, a lotion, a spray, or an ointment.
17. The method according to claim 16, wherein said transdermal formulation is a patch formulation comprising an adhesive polymer.
18. The method according to claim 17, wherein said contacting comprises adhering said patch formulation to a forehead skin of the individual.
19. A transdermal formulation comprising:
a) an adhesive layer comprising an indole serotonin receptor agonist; andb) a backing layer.
20. The transdermal formulation of claim 19, wherein said agonist is present in an amount of from about 0.5 weight % to about 50 weight %
21. The transdermal formulation according to claim 19, wherein said formulation further comprises a hydrophobic oil.
22. The transdermal formulation according to claim 21, wherein said hydrophobic oil is present in an amount of from about 2 weight % to about 50 weight
23. The transdermal formulation of claim 19, wherein said indole serotonin receptor agonist is selected from sumatriptan, frovatriptan, zolmitriptan, eletriptan, rizatriptan, naratriptan, and almotriptan.
24. The transdermal formulation of claim 21, wherein said hydrophobic oil is selected from a higher fatty acid ester, an oil, a fat, a higher fatty acid, and a higher alcohol.
25. The transdermal formulation of claim 19, wherein the adhesive layer further comprises a transdermal absorption enhancing agent in an amount of from about 0.01 weight % to about 20 weight %.
26. The transdermal formulation of claim 25, wherein said absorption enhancing agent is selected from lauric acid diethanolamine, tetraethyl glycol laurate, glycerol monolaurate, sorbitan trioleate, and a polyol.
27. The transdermal formulation of claim 19, further comprising a detachable protective layer.
Patent Application
20070140977
